Pierre Fabre Invest, the dedicated investment subsidiary of Pierre Fabre Invest, is the French pharmaceuticals- and cosmetics company.
Gennisium’s company mission is to provide newborn patients with suitable medicines, based on affordable prices and with global reach. Gennisium is attempting to reposition existing molecules for neonatal indications. Gennisium also aims to provide neonatal intensive care units and health care professionals with novel formulations to treat and prevent neonatal diseases.
Franck Pigache, CEO, Gennisium Pharma, commented: “We are very pleased with this investment and to now have such a strong partner as Pierre Fabre among our shareholders – a major player and a successful company with solid experience in the pharmaceutical industry and the specific field of pediatrics. Gennisium will now have more resources and flexibility to grow with their support. New drugs are under development and Pierre Fabre’s investment will allow us to accelerate the registration and availability of those products.”
Pierre Fabre, in addition to dermatology and oncology, is now involved in rare diseases. He focuses on diseases that affect newborns and develops prophylactic and specific therapies for these patients. This is how infantile hemangioma has been treated since 2014, and XLHED in recent years. This rare genetic disease affects baby boys’ sweat, respiratory, skin, and teeth.
Eric Ducournau, CEO, Pierre Fabre Group, said: “We are delighted to be working with Gennisium Pharma, a young, innovative pharmaceutical company developing formulations for premature babies and niche markets. Through this investment, we confirm our willingness to explore new opportunities in the field of rare pediatric diseases where patient and family needs remain immense.”
Both companies have already begun to work together to provide therapeutic advances for this vulnerable population. Gennisium has a strong partner in Pierre Fabre who has global experience and connections in the pharmaceutical sector to accelerate its development in neonatology.
Pierre FabreGennisium will be able to expand its product range, its organization, and its market access around the world by investing in existing operations, licensing agreements, and expert sharing in the field neonatology/pediatrics.
GennisiumThe company aims to manage key and important strategic functions in-house, including Marketing, Regulatory Affairs and Medical, as well as Commercialization and Marketing of drugs. It also has its own sales force in key European and Export countries.
Source: newbusinessethiopia
